ALDX FDA decision — Mar 17, 2026
✕ COMPLETE RESPONSE LETTER
Aldeyra Therapeutics Inc. — Reproxalap (ADX-102) - (CHAMBER) · Dry Eye Disease.
Run-up into the decision (T-120 → T+5) PDUFA 3/17/26 $5.74 $3.99 9/30/25 Daily close, T-120 (9/30/25) through T+5. Run-up high $5.74 on 10/10/25, low $3.99 on 12/19/25 (T-120 to T-1). FDA decision 3/17/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-03-17
Outcome CRL
Drug / candidate Reproxalap (ADX-102) - (CHAMBER)
Company Aldeyra Therapeutics Inc.
120-day run-up (T-120→T-1) -17.2%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio